If it feels like everyone around you in Delhi has had a cough that just won’t go away this monsoon, you’re not imagining it. The city has recorded 2,308 confirmed H1N1 cases as of August 25, along with more than 600 additional influenza cases, pushing the total reported flu burden in the capital to nearly 3,000. To put that in perspective, Delhi had logged just 229 H1N1 cases during the same stretch last year. That’s not a modest uptick; it’s close to an eightfold jump, and it’s enough to have rattled the city’s health administration into action.

From a Trickle to a Flood

The numbers didn’t creep up slowly either. Cases had already crossed 1,344 in the first half of August, then climbed to 1,777 by August 20, before jumping again to 2,308 just five days later. That kind of week-on-week acceleration is what pushed Chief Minister Rekha Gupta to call an emergency review meeting with senior health officials, along with representatives from the MCD, NDMC, and the Delhi Cantonment Board. Health Minister Pankaj Kumar Singh briefed reporters after the meeting, stressing that hospitals have enough doctors, staff, and medicine, and that the situation, while serious, is being actively managed rather than spiraling out of control.

For many residents, the illness has followed a familiar pattern this year: a cough that lingers far longer than expected, a sore throat, body aches, and a fever that refuses to break for days. What’s changed is how many of these everyday symptoms are now testing positive for H1N1 specifically, rather than just being written off as a seasonal cold. Doctors say the classic warning signs of swine flu, fever, cough, sore throat, headache, body aches, and fatigue, are showing up in far more patients this year than last, and hospitals across Delhi-NCR are reporting a noticeably higher volume of flu-like admissions through the monsoon season.

Delhi’s Response on the Ground

In response, the Delhi government has designated dedicated hospital wards for flu patients, including ICU and ventilator beds, to make sure serious cases don’t get turned away. Officials have also warned hospitals against refusing beds to patients who need them, framing it as a red line the administration is prepared to enforce with strict action if necessary. Schools haven’t been left out either: the Directorate of Education has rolled out a “Healthy School-Healthy Community” advisory urging students and staff to maintain respiratory hygiene, and the Delhi Medical Association has separately recommended N95 masks in crowded or high-risk settings.

The public health messaging has been fairly consistent across officials and doctors alike: mask up in crowded spaces, don’t self-medicate, and see a doctor promptly rather than waiting out a fever that isn’t improving. That last point matters because H1N1, while usually manageable, can turn serious quickly in certain groups. Children, the elderly, pregnant women, and people with chronic illnesses are considered the most vulnerable to severe complications, and doctors have specifically flagged those groups for extra caution this season. Encouragingly, no official deaths from H1N1 have been confirmed in Delhi so far this year, even as the case count climbs.

Should People Actually Be Worried?

Health experts have tried to strike a careful balance between urgency and calm. Public health specialists have pointed out that there’s no evidence the virus itself has mutated into something more dangerous, and that this year’s spike looks consistent with normal seasonal influenza patterns tied to the monsoon rather than any new, more virulent strain. Most patients, according to doctors, recover fine with rest, fluids, and standard symptomatic care. At the same time, physicians are cautioning against two opposite mistakes: panicking over every fever or cough, and dismissing symptoms that are clearly getting worse. If a fever persists, breathing becomes difficult, or fatigue feels unusually severe, that’s the point to seek medical attention rather than try to wait it out at home.

There’s also a reasonable expectation that this wave will ease as the season shifts. Former AIIMS director Dr. Randeep Guleria has said he expects H1N1 cases in Delhi to decline once the monsoon recedes, which lines up with how influenza typically behaves in North India. Still, the sharp rise has revived interest in seasonal flu vaccination, with doctors noting a jump in enquiries, particularly from high-risk individuals and families looking to get ahead of the illness before winter sets in.

Delhi isn’t alone in dealing with this seasonal spike, either. Chennai and other parts of the country have reported a broader rise in flu activity this monsoon, suggesting this is less a Delhi-specific anomaly and more a nationwide pattern this year. For now, the message from both the government and the medical community is consistent: stay alert, take basic precautions like masking in crowded places, get tested if symptoms persist, and avoid the urge to self-medicate through what might feel like “just another cold.” With hospital wards on standby and case numbers still climbing, health officials are hoping vigilance now will keep this flu season from becoming anything worse than an unusually busy one.

The post Delhi’s H1N1 Cases Surge to Nearly Eight Times Last Year’s Levels. appeared first on POLYTIKAL.

Nepal is going through one of its worst monsoon disasters in years. A series of flash floods tore through the Rasuwa and Nuwakot districts on the morning of August 26, and by the time rescue teams could even get a proper look at the damage, the human cost was already staggering. As of the latest count, at least 95 people have died in Nepal, with three more confirmed dead across the border in China. Hundreds of others, including foreign trekkers and tourists who were in the region for the Himalayan trails, are still unaccounted for.

What makes this disaster particularly frightening is how it came together. Officials believe a combination of factors triggered the floods: unusually heavy rainfall, a suspected glacial lake outburst flood (GLOF) near the Nepal-China border, and a minor earthquake that appears to have set off avalanches in the upper catchment areas. Water from the Bhotekoshi and Trishuli river systems surged downstream with almost no warning, swallowing entire settlements along the way. In Nuwakot alone, floodwaters tore through commercial hubs like Betrawati, Trishuli Bazaar, Dhunge, and Devighat, leaving behind a trail of collapsed buildings, washed-out roads, and families with nowhere to go.

The scale of the destruction to Nepal’s infrastructure is hard to overstate. Six major hydropower and transmission facilities, including the Rasuwagadhi and Chilime plants along with the Trishuli 3A and 3B stations, have been damaged or knocked offline entirely. That’s not just an inconvenience; it’s a hit to a country that depends heavily on these projects for both domestic electricity and export revenue. The Nepal Army, Armed Police Force, and Nepal Police have all been mobilized, backed by helicopters and medical teams, but the disrupted phone and internet networks in the affected districts have made search and rescue painfully slow.

India Watching the Rivers Closely

Given that several of these rivers don’t stop at the border, India wasted no time putting its own emergency machinery on alert. Union Home Minister Amit Shah spoke directly with the Chief Ministers of Uttar Pradesh and Bihar to discuss the downstream risk, since the same water eventually flows into the Gandak and other river systems that run through northern India. The Central Water Commission flagged a sudden rise in the Trishuli river’s level near Furke Khola, roughly 160 kilometers from the Indian border, and warned that the Gandak could see waves rising by as much as three meters as the floodwater makes its way south.

That warning was enough to trigger a rapid response on the ground. Nearly 5,000 people have already been evacuated from six flood-prone districts in Bihar as authorities keep a close watch on rising water levels. West Champaran, East Champaran, Gopalganj, Saran, Muzaffarpur and Vaishali districts have been placed under special vigilance and district magistrates have been asked to keep a vigil on the embankments, low-lying pockets, bridges and culverts round-the-clock. The districts of Sitamarhi and Sheohar are also under close watch because both have a history of flooding whenever the Gandak swells.

The National Disaster Response Force and State Disaster Response Force have both been placed on standby, with at least one NDRF team already sent to Gopalganj and more expected to follow depending on how the situation develops. Bihar’s Water Resources Department has also opened dozens of gates at the Gandak Barrage in Valmikinagar to let the river discharge safely rather than risk a sudden embankment breach, something the state has dealt with painfully in past monsoon seasons. Uttar Pradesh’s administration, under Chief Minister Yogi Adityanath, has echoed similar precautions along its own stretch of the border.

Officials on the Indian side have been careful to strike a balance between urgency and calm. The Home Ministry’s messaging has repeatedly stressed that there’s no need for panic, even as evacuation drives continue and community kitchens and relief shelters are kept ready in vulnerable pockets. According to the Central Water Commission, reservoir levels on the Nepal side have actually started reducing, which officials are reading as a cautiously positive sign that the worst surge may already be behind the border regions, even if the danger hasn’t fully passed for India’s low-lying districts.

A Familiar but Deadly Pattern

For people living along the Nepal-Bihar border, this kind of scare isn’t new. Nearly every monsoon season brings some version of this story: heavy rain upstream in Nepal, a swollen Gandak or Kosi, and anxious families in northern Bihar watching the water rise. What sets this year apart is the sheer speed and violence of the flooding, driven by that rare combination of a glacial lake outburst and seismic activity striking almost at once, and just how high the death toll has already climbed in Nepal itself.

For now, the focus on the ground remains split between two urgent tasks: Nepal’s rescue teams are racing against time to find those still missing in Rasuwa and Nuwakot, while Indian authorities in Bihar and Uttar Pradesh are doing everything they can to make sure this tragedy doesn’t repeat itself downstream. With monsoon clouds still hanging over the Himalayan foothills, both sides know there’s little room for complacency in the days ahead.

The post India Rushes Aid as Nepal Flood Death Toll Nears 100. appeared first on POLYTIKAL.

A new Swedish study is giving public health researchers one of the clearest signals yet that a simple, at-home test really can save lives. Researchers at Karolinska Institutet and Umeå University followed more than 376,000 people for up to 14 years and found that those who actively participated in colorectal cancer screening had a 43% lower risk of dying from the disease compared to those who didn’t. The findings, published in JAMA Network Open, add significant weight to ongoing calls for wider adoption of routine screening programs.

What the Study Actually Found

The research drew on data from Sweden’s Stockholm–Gotland screening program, one of the country’s earliest regional efforts, which launched in 2008. Researchers compared people who were invited to screening between 2008 and 2012 against a control group made up of individuals who either received their invitation later or hadn’t been invited at all. By following both groups through Swedish national health registers, the team was able to track the diagnoses and deaths from cancer for a long period of time, in some cases up to 14 years.

In total, the study included 376,511 individuals, and 1,668 deaths from colorectal cancer were recorded during the follow-up window. After adjusting for statistical factors like people in the control group eventually being invited later, or invited individuals never actually participating, the researchers arrived at two separate figures. Simply receiving an invitation to screening was linked to a 26% lower risk of dying from colorectal cancer. But for people who actually completed the screening, that risk reduction jumped to 43%.

Why Participation Made Such a Difference

According to Johannes Blom, one of the study’s authors and a senior consultant involved in the research, earlier evaluations of the program had estimated a more modest 14% reduction in mortality tied to receiving a screening invitation. With longer follow-up data and more refined statistical methods, the benefit tied to actual participation turned out to be considerably larger. It’s a distinction that matters: an invitation alone doesn’t protect anyone. It’s the act of completing the test that appears to drive the bulk of the benefit.

The mechanics of the test itself are fairly straightforward. Eligible residents, generally those between ages 60 and 74, are mailed a screening kit and asked to provide a small stool sample, which is then analyzed for traces of blood not visible to the naked eye. If blood is detected, the person is typically referred for a colonoscopy to investigate further. Colorectal cancer tends to have a much better prognosis when caught early, particularly before it has had a chance to invade deeper into the bowel wall or spread elsewhere, which is exactly the kind of early detection this at-home test is designed to catch.

The Participation Gap Researchers Are Worried About

Despite the test being free and relatively simple to complete, the researchers note that roughly a third of people who are invited never actually submit a sample. That gap is part of what makes this study so relevant beyond Sweden’s borders. If a screening program with strong infrastructure and universal access still sees a third of eligible participants opting out, it raises real questions about how to close that gap, whether through better public messaging, reminders, or simply making the process even easier.

Blom pointed to this participation shortfall directly, noting that the findings highlight the importance of actually completing colorectal cancer screening rather than just being offered the opportunity to do so. The data suggest that there can be a large difference in survival outcomes between an invitation sitting unopened on a kitchen counter and a completed test mailed back.

Strengths and Limitations of the Study

One of the main strengths of the study is its scale. With over 376,000 people followed for over a decade and the extensive national health registers in Sweden, researchers have a level of statistical power that smaller or shorter studies simply can’t match. However, the researchers caution that their results are based on statistical adjustments for various sources of bias rather than on a real-time randomized trial. People who elect to be screened may not be the same as those who do not in ways that cannot be fully controlled for, such as in their overall health habits or contact with the health care system. That means some uncertainty remains, even with the size and rigor of this analysis.

What This Means Going Forward

Colorectal cancer remains one of the most commonly diagnosed cancers worldwide, and this kind of large-scale cancer prevention study offers real-world evidence that population-based screening programs can meaningfully reduce deaths. For health systems weighing whether to expand or improve their own colorectal cancer screening infrastructure, the Swedish results offer a compelling data point: a low-cost, at-home test, when actually completed, appears to be strongly associated with a lower risk of dying from the disease.

The bigger challenge now may not be building the infrastructure but boosting participation. As this research shows, the benefit of screening isn’t just about offering the test. It’s about the roughly two-thirds of people who send their sample back, and finding ways to bring more of the remaining third along with them.

This article discusses cancer screening and mortality research. If you are experiencing anxiety around a personal health situation, it’s worth speaking with a doctor or another healthcare professional who can advise on your individual circumstances.

The post Colorectal Cancer Screening Cuts Death Risk by 43%. appeared first on POLYTIKAL.

Health authorities in West Bengal are closely monitoring the situation after confirming cases of Nipah virus infection in the state, notably among healthcare workers who were treating patients before falling ill themselves. The confirmation has prompted a swift and well-coordinated response with rapid contact tracing and containment measures rolled out almost immediately to prevent any further spread.

For those following Nipah virus West Bengal developments, the story is in some ways a familiar one, even if each outbreak throws up its own set of anxieties. The health workers, working at a private hospital in North 24 Parganas district, developed symptoms which progressed rapidly, prompting immediate isolation and testing. And what followed was a textbook case of how India’s health surveillance system is supposed to respond to exactly this kind of threat.

A Quick and Comprehensive Answer

Once the infections were confirmed, authorities wasted no time. Nearly 200 people who had been in contact with the patients were identified, traced and tested – a major undertaking that reflects just how seriously health officials treat any hint of Nipah transmission. All of those contacts have tested negative and there have been no new cases since, which is reassuring. This strongly points to the containment measures having done their job, at least for this specific cluster.

A national response team was also sent to work with state health officials, adding additional expertise and resources to manage the situation on the ground. Such centre-state coordination has become the hallmark of India’s response to outbreaks of this nature, having learned from previous Nipah events, especially from Kerala, which has had to deal with recurring spillovers over the last few years.

Experts say it’s not a new, growing threat

One of the more reassuring aspects of this Nipah outbreak India 2026 episode is the broader context that experts have given around it. Public health specialists have been quick to point out that outbreaks like this tend to follow pretty predictable patterns, closely tied to local environmental and cultural factors rather than signaling some kind of new or escalating danger.

Fruit bats are the natural hosts of Nipah virus and human infections usually occur through direct contact with these animals, or more commonly, through consumption of food or drink contaminated with bat saliva or droppings – raw date palm sap has been a particularly well-documented example in past outbreaks across the region. This knowledge of the transmission pathway is crucial in effective control of bat-borne viruses as it allows health officials to focus on the specific behaviors and seasonal patterns that open opportunities for the virus to pass on from animals to humans.

Crucially, while human-to-human transmission is possible, it generally requires very close contact with someone who is already symptomatic — hence why healthcare workers, who are often in close contact with patients during the most infectious stages of illness, remain among the higher-risk groups even while the wider public is at little risk.

Global risk of transmission Very low

While any case of Nipah is worrying because of the high fatality rate, the health authorities and international agencies have maintained that the risk of this outbreak spreading outside India is very low. This assessment is more than just a reassurance to settle frayed nerves. It is grounded in the specific epidemiology of the virus, which simply does not spread as easily or as far as viruses that are primarily airborne.

However, some countries in the region and neighboring countries have taken precautionary measures such as increasing screening at points of entry, which is a prudent, proportionate response, rather than alarm.

The search for a vaccine continues The most important long-term challenge highlighted by this episode is the continuing absence of an approved vaccine or antiviral treatment for Nipah virus. The virus has led to sporadic outbreaks in South Asia for over two decades, but medical science has yet to develop a licensed tool to prevent or directly treat it.

But there is some reason for optimism. Some vaccine candidates are promising now in animal trials, and researchers are hopeful that ongoing investment will eventually lead to a viable option for humans. But that takes sustained funding and real international research collaboration – the kind of long-term commitment that is hard to sustain once the initial headlines fade and public interest wanes.

Why Vigilance Should Continue

This latest cluster of cases is a useful reminder that diseases like Nipah do not have to cause massive outbreaks to be a cause for serious concern. The early detection by India’s surveillance systems, efficient contact tracing and prevention of further spread is a public health success story in itself that needs to be acknowledged.

It also highlights why sustained investment in surveillance infrastructure, laboratory capacity and research on treatments cannot be considered as optional extras. Nipah virus may not be a widespread threat at the moment, but its high fatality rate and unpredictable emergence pattern means that the systems put in place to catch it early are doing the exact kind of quiet, essential work that rarely makes headlines until something goes wrong. For now, West Bengal’s experience shows that when those systems work as they should, even a serious virus like Nipah can be contained before it becomes a much bigger crisis.

The post India steps up surveillance following Nipah virus cases in West Bengal. appeared first on POLYTIKAL.

The number of confirmed Ebola cases in the Democratic Republic of Congo’s Ituri province has crossed the grim milestone of 4,000. It’s the fastest-spreading Ebola outbreak ever, say the health officials and aid workers on the ground, and the numbers are rising every day. This started as a local health scare in a remote mining region, and in only a few months has snowballed into one of the most serious outbreaks the world has seen for years.

For those following the story of the Ebola outbreak DRC 2026, the magnitude of this crisis is hard to overstate. It is the second biggest Ebola epidemic ever after the devastating epidemic in West Africa in 2014-2016. The really scary thing about this one is not just how many people have gotten sick, but how fast it’s been growing – faster than any outbreak we’ve seen before in terms of how fast the number of infections has gone up.

Women and Children Pay the Heaviest Price But what makes this crisis the most heartbreaking is who it’s impacting the hardest. Women and children continue to make up a disproportionate share of those affected, a pattern that has been repeated in past Ebola outbreaks across Africa but remains no less devastating each time. Pregnant women are particularly vulnerable and often cannot find the specialized care they need even under normal circumstances, let alone during a raging epidemic. Children, in the meantime, are especially vulnerable to the virus itself and the disruption it causes to already fragile health care systems.

This is not a statistic buried somewhere in a health ministry report – this is families being torn apart, this is caregivers falling ill trying to look after loved ones, this is communities losing their most vulnerable members at an alarming rate.

Almost a Million People Displaced

And the outbreak itself has created a massive humanitarian crisis of its own, separate from the direct health impact. Almost a million people have been displaced, families leaving affected areas and seeking safety in less affected areas. This sort of mass displacement breeds a vicious circle – as people migrate they risk carrying the virus to new communities, while also straining resources in the places where they have sought refuge.

Insecurity and conflict have ravaged Ituri province for a long time, making the situation all the more complicated. Violence by armed groups in the region has made it very dangerous for health workers to reach some of the worst-affected communities, delaying efforts to trace contacts, treat and contain new flare-ups before they can spread further.

WHO declares global health emergency

The World Health Organization upgraded the situation to a Public Health Emergency of International Concern – the agency’s highest level of alert, used only for crises that pose a real risk of spreading across borders, given the scale and speed of the outbreak. The WHO declaration of a public health emergency has helped unleash a wave of international support, from funding and medical supplies to specialist teams being deployed directly into affected zones.

That international mobilization is under way. Containment efforts are being stepped up in the most affected health zones, treatment centers are being expanded to cope with the growing number of patients and vaccine deployment campaigns are underway in an effort to slow transmission. But it’s a race against time – health workers on the ground have repeatedly warned the virus is spreading faster than response efforts can keep up with in some areas.

a difficult virus to fight

The strain of the virus itself adds to the challenge. This outbreak, unlike some past Ebola outbreaks in the region, includes a strain that current vaccines and treatments were not originally made to target, so health authorities need to rely on newer trials and adapted protocols, rather than only on tools that worked in the past. That has slowed the pace of the response in ways that have frustrated public health officials who know how critical speed is in terms of containing Ebola.

Why This Matters Outside the DRC

This is no remote tale from one side of Central Africa. The rapid spread and rising number of Ebola cases in Africa this year demonstrate how quickly a localized outbreak can turn into a global health crisis if containment efforts lag. Cases linked to this outbreak have already been detected outside the borders of the DRC, a reminder of how connected travel and trade routes can carry a virus far from its source.

Health officials continue to emphasize that international cooperation, sustained funding and a rapid on-the-ground response are still needed to get this outbreak under control before it gets any larger. For the communities that are directly affected, however, the crisis is already personal — families displaced from their homes, health workers risking their safety to save others, and a death toll that continues to rise week after week.

The next few weeks will be crucial in determining whether the outbreak can be contained, or whether it continues on its present trajectory as one of the worst Ebola epidemics in history.

The post Confirmed cases of Ebola outbreak in DRC exceed 4,000. appeared first on POLYTIKAL.

For years, one of the most frustrating aspects of long COVID has been how little doctors could explain about it. Patients would describe fatigue that never lifted, brain fog that clouded ordinary tasks, and a grab-bag of symptoms that didn’t fit neatly into any single diagnosis. Now, a major new study published in Nature offers a compelling piece of the puzzle: COVID-19 doesn’t just attack the body on its own. It appears to wake up other viruses that have been lying dormant for years, and that reactivation may be quietly driving some of the most stubborn post-COVID symptoms.

The research, led by scientists at the University of Texas at Austin’s Dell Medical School and Boston Children’s Hospital, working alongside a consortium of 15 biomedical institutions across the United States, drew on data from 1,154 hospitalized COVID-19 patients enrolled in the Immunophenotyping Assessment in a COVID-19 Cohort, or IMPACC, study. Researchers collected blood samples, nasal swabs, and lung fluids from patients treated at 20 hospitals between May 2020 and March 2021, generating over a billion data points in the process. What they found reshapes how scientists think about what a severe COVID-19 infection actually does inside the body.

Nearly half of the patients studied showed evidence of at least one reactivated dormant virus within the first 40 days after hospital admission. In total, the team identified 11 different reactivated viruses, with the most commonly detected being Epstein-Barr virus, herpes simplex virus 1, cytomegalovirus, and a group of viruses called Anelloviridae. Most people carry several of these chronic, generally harmless viruses without ever knowing it. Epstein-Barr virus alone infects more than 90% of adults worldwide at some point in their lives, typically staying quiet in the body after the initial infection resolves. But under the stress of a severe COVID-19 illness, these viruses appear to stir back to life.

What’s particularly striking is the timing pattern researchers uncovered. These viruses didn’t all reactivate simultaneously. Epstein-Barr virus tended to peak early, often detectable near the time of hospital admission before gradually declining. Cytomegalovirus and herpes simplex virus 1, by contrast, tended to show up roughly three weeks later. Anelloviridae followed yet another pattern, remaining steady for about 20 days before slowly tapering off. This staggered timeline suggests the reactivations aren’t random noise, but rather follow some kind of coordinated biological sequence tied to how the immune system responds to COVID-19 over time.

Perhaps the most medically significant finding involves that poorly understood Anelloviridae family. While these viruses don’t cause any proven disease on their own and are carried by the vast majority of adults, their reactivation was strongly associated with long-term physical disability and long COVID, defined in the study as symptoms persisting at least four weeks after the initial infection. That’s a meaningful clue for a condition that has remained maddeningly difficult to diagnose, let alone treat, and it opens a fresh angle for post-COVID syndrome research that hasn’t been available until now.

The study also challenges a longstanding assumption in immunology. Researchers had generally believed that dormant viruses reactivate mainly when the immune system is suppressed, whether from illness, medication, or other stressors. But the analysis found that Epstein-Barr virus and cytomegalovirus reactivated in these patients in connection with inflammation, not immune suppression. In other words, reactivation happened even in people whose immune systems appeared to be functioning normally, simply because their bodies were dealing with intense systemic inflammation. That’s a genuinely new mechanism, and one that researchers say could reshape how scientists think about viral reactivation during any severe illness, not just COVID-19.

Reactivation of these dormant viruses was also linked to more severe COVID-19 outcomes overall, including increased risk of death, adding another layer to why this discovery matters beyond the long COVID connection alone. The researchers are careful to note that their findings show correlation, not proof of causation. It’s still not established that reactivated viruses directly cause long COVID’s lingering symptoms, and the patients studied were unvaccinated and largely infected during the early phase of the pandemic, before the emergence of later variants and before most of the global population had built up immunity through vaccination or prior infection. Whether the same pattern holds for people infected with more recent strains, or for those with milder illness, remains an open question.

Even so, researchers involved in the work believe the implications are significant. Ofer Levy, director of the Precision Vaccines Program at Boston Children’s Hospital and a site principal investigator on the study, pointed out that COVID-19 remains a real public health burden even now, noting that up to 50,000 Americans died during the 2025-2026 respiratory season and that estimates suggest more than 10 million U.S. adults may be living with long COVID. The next phase of research, he said, will focus on understanding exactly how the immune system responds to these reactivated viruses throughout the course of COVID-19, with the goal of identifying which patients might benefit from targeted antiviral treatment and figuring out the optimal timing for such interventions.

For a field that has struggled to offer patients clear answers, this study represents real progress. It won’t immediately translate into a treatment for long COVID, but by mapping which viruses reactivate, when, and under what immune conditions, researchers now have a far more detailed roadmap than they did before. That roadmap could eventually guide new diagnostic tests capable of identifying which patients are at higher risk of lasting symptoms, and which therapies might actually help them recover.

The post New Study Links COVID-19 to Reactivation of Dormant Viruses, Offering Fresh Clues on Long COVID. appeared first on POLYTIKAL.

For a state that has now weathered Nipah virus outbreaks nearly every year since 2018, Kerala’s health authorities have developed something rare in public health: a practiced, almost muscle-memory response to a disease with no cure. That response is being tested again in 2026, after a case of Nipah virus Kerala health officials confirmed in Kozhikode district earlier this year triggered a familiar, well-rehearsed cycle of containment, contact tracing, and cautious public messaging.

The Case That Set Off the Alert

The patient, an adult male resident of Kozhikode, developed symptoms in late May and was hospitalized about ten days later, on June 10. Unusually, his presentation was primarily neurological rather than respiratory — confusion and other signs affecting the brain, without the cough or breathing difficulty that mark many other Nipah cases. He was placed on ventilator support in intensive care as doctors worked to confirm the diagnosis, which the Kerala State Health Department did on June 11, notifying the World Health Organization the same day.

What followed was a large-scale, methodical operation. Within a week, contact tracing India has become known for in Nipah situations had identified 104 contacts of the patient — a mix of family members, healthcare workers, and others who may have had direct or indirect exposure. Of those, four were classified as very high-risk, 14 as high-risk, and 86 as low-risk, with 45 of the total being healthcare workers who treated or came near the patient before diagnosis. Every one of those contacts was placed under active monitoring, with health workers following up twice daily to check for early symptoms.

The result so far has been reassuring: no secondary transmission has been detected among any of the tracked contacts. For a virus capable of jumping from person to person through close contact with an infected patient’s bodily secretions, that’s a meaningful outcome, and it speaks to how quickly Kerala’s surveillance systems kicked into gear once the case was confirmed.

A Recurring, Not a New, Threat

This is not Kerala’s first encounter with Nipah, and it likely won’t be its last. Since the virus was first identified in the state in 2018 — when an outbreak killed a significant share of those infected — Kerala has recorded additional flare-ups in 2019, 2021, 2023, 2025, and now 2026, almost all concentrated in and around Kozhikode district. Health officials attribute this recurring pattern to the district’s ecology: it supports large populations of fruit bats, the natural reservoir species for the virus, which creates repeated opportunities for spillover into humans, whether through contaminated fruit, contact with infected pigs, or other exposure routes tied to the bats’ habitat.

The seasonal timing also tracks a pattern researchers have noted before, with cases tending to cluster between April and September. Rather than treating each outbreak as an isolated emergency, Kerala has essentially built standing infrastructure around the expectation of recurrence: rapid response teams at both state and central levels, established laboratory capacity for fast diagnosis, and protocols that kick in automatically the moment a suspected case is flagged.

Experts Weigh the Risk

Despite the seriousness of any confirmed case — Nipah has historically carried extremely high fatality rates in past Kerala outbreaks — public health experts monitoring this latest episode describe the risk of wider community spread as low, at least for now. That assessment rests heavily on the fact that no secondary cases have emerged despite over a hundred contacts being tracked, suggesting the containment measures put in place immediately after diagnosis have worked as intended.

That said, experts are careful not to frame “low risk” as “no risk,” or as a reason to ease up on vigilance. National teams from the National Centre for Disease Control and the Indian Council of Medical Research visited Kozhikode within days of the case being confirmed, underscoring how seriously the zoonotic disease outbreak is being treated at the national level even as the immediate numbers remain contained.

The Bigger Gap: No Cure, No Vaccine

What makes each Nipah case so tense, regardless of how well-contained it ultimately proves to be, is the absence of any approved treatment. There’s no antiviral specifically approved for Nipah, and no vaccine has yet cleared the finish line for public use, despite years of research interest sparked by outbreaks in Kerala, Bangladesh, and elsewhere in South and Southeast Asia. Doctors treating confirmed patients are limited to supportive care — managing symptoms, providing ventilator support, and hoping the patient’s own immune system can fight off a virus that, in past Kerala outbreaks, has killed a large share of those infected.

This gap is exactly why public health specialists keep returning to the same message after every outbreak: contact tracing and surveillance can contain a single spillover event, but they can’t eliminate the underlying threat. Sustained investment in viral infection surveillance, faster diagnostic pipelines, and — most critically — vaccine development are what officials and researchers say will ultimately be needed to move Kerala’s response from “very good containment” to genuine prevention.

What Comes Next

For now, the current case remains a contained, closely watched situation rather than a spreading outbreak. Kerala’s health department continues to track the recovering pool of contacts, and no WHO health alert beyond routine outbreak notification has been escalated. But with this marking yet another entry in an unbroken string of near-annual outbreaks stretching back to 2018, there’s a growing recognition among health authorities that Kozhikode’s relationship with Nipah virus isn’t a series of unlucky one-off events — it’s a pattern the region will likely keep confronting until more durable medical tools become available.

The post Kerala on Alert as Nipah Virus Pattern Continues in 2026. appeared first on POLYTIKAL.

India’s health system is once again on alert after confirmed cases of Nipah virus surfaced in West Bengal earlier this year, part of a pattern that has also touched Kerala in recent months. While the immediate outbreak has been contained to small, healthcare-linked clusters, officials aren’t taking any chances — surveillance teams are still tracking contacts, testing suspected cases, and watching closely for any sign the virus is spreading beyond where it’s already been found.

The West Bengal cases were first flagged in Barasat, a town in the North 24 Parganas district, after two nurses working at the same private hospital fell ill in late December with symptoms that quickly progressed to neurological complications. Lab confirmation came from the National Institute of Virology in Pune in mid-January, and additional cases followed as investigators traced the chain of transmission within the hospital. Several of those infected were healthcare workers themselves, which pointed to hospital-based transmission rather than a fresh spillover from animals — a distinction that matters a lot for how authorities respond.

That’s because Nipah virus is, at its core, a zoonotic disease. It originates in fruit bats and can jump to humans either directly, through contact with an infected animal, through contaminated food like raw date palm sap, or — as appears to have happened in this case — through close contact with an already-infected person. West Bengal sits near bat reservoir zones along the India-Bangladesh border, which is part of why the state has seen sporadic Nipah activity going back to outbreaks in 2001 and 2007. Kerala, on the other side of the country, has dealt with its own recurring pattern of spillovers nearly every year since 2018, most recently with a confirmed case in June.

What makes Nipah such a serious concern, even in small numbers, is the sheer severity of the disease itself. Case-fatality rates run anywhere from 40% to 75%, among the highest of any known human pathogen, and there’s still no licensed vaccine or antiviral treatment available anywhere in the world. Infections typically start out looking like a bad flu — fever, headache, muscle aches — before some patients progress to viral encephalitis, a dangerous inflammation of the brain that can cause seizures, confusion and, in severe cases, coma. It’s this jump from “flu-like” to “critical” that makes early detection so important, and why India’s health ministry has leaned so heavily on aggressive contact tracing every time a case is confirmed.

So far, that approach appears to be working. Health officials say all traced contacts linked to the West Bengal cluster have tested negative, and there’s no evidence right now of sustained human-to-human transmission outside the original hospital setting. The World Health Organization has assessed the risk at the sub-national level in West Bengal as moderate, largely because of the ongoing presence of bat populations in the area, but has kept the broader national, regional and global risk rating at low. Simply put, this looks like a contained, closely watched cluster rather than the start of something bigger — though health authorities are clearly not treating that as a reason to relax.

The response on the ground has been substantial. India’s Ministry of Health and Family Welfare deployed a national outbreak response team to support West Bengal’s state health department, and confirmed patients were moved to a specialized infectious diseases facility in Kolkata for isolation and treatment. Nearly a hundred people connected to the hospital were placed under quarantine as a precaution while testing was carried out. Internationally, the ripple effects were felt too — several countries in Southeast Asia, along with Nepal, introduced temporary airport screening for travelers from the affected region, even though the WHO has stopped short of recommending any formal travel or trade restrictions.

For a country that has now dealt with Nipah outbreaks in two very different states, the pattern is starting to reveal something useful about how India manages this kind of threat. Research comparing West Bengal and Kerala has found that despite sharing the same bat reservoir, the two states have had very different outcomes — Kerala’s frequent spillovers have rarely spread beyond small clusters thanks to strong surveillance and a “One Health” approach linking animal, human and environmental monitoring, while West Bengal’s more limited history of outbreaks allowed this latest cluster to spread within a hospital before it was caught. That gap suggests the difference between a contained scare and a larger public health crisis often comes down to how fast health systems can spot and isolate cases.

With no vaccine or specific treatment on the horizon anytime soon, surveillance remains India’s strongest tool against Nipah virus. Health officials continue to stress that the overall risk to the public is low and that there’s no cause for panic, but the virus’s high fatality rate means every new case gets treated with real urgency. As monitoring continues in both West Bengal and Kerala, the message from public health authorities is consistent: stay alert, report symptoms early, and let the surveillance systems that have worked before do their job again.

The post Nipah Virus Cases Reported in West Bengal, Health Authorities Ramp Up Surveillance. appeared first on POLYTIKAL.

Nearly three months into what has become one of the worst Ebola crises in recorded history, the Democratic Republic of Congo is racing against time on two fronts at once — containing a virus that keeps outpacing every effort to slow it down, and pushing forward experimental treatments and vaccines faster than has ever been attempted during an active outbreak. The DRC Ebola outbreak 2026 has now become the second-largest on record, and health workers in the country’s northeastern Ituri province are bearing much of the human cost.

A Fast-Moving, Unusual Outbreak

The outbreak was first confirmed on May 15, when laboratory tests identified the Bundibugyo virus in samples from patients in Ituri’s Mongbwalu and Rwampara health zones. It’s the 17th Ebola outbreak the DRC has faced since the disease was first identified in 1976, but this one has moved differently from the ones before it. By the end of July, it had already become the fastest-spreading Ebola epidemic ever recorded, and it has since crossed a grim milestone: more than 3,800 confirmed cases and over 1,750 deaths, according to the latest figures reported by health authorities. Ituri province alone accounts for close to 90 percent of all reported cases, though infections have also turned up in North Kivu, South Kivu, Haut-Uele, and Tshopo, including in the major city of Kisangani.

What makes this outbreak especially difficult is the strain behind it. Unlike the more familiar Zaire ebolavirus, which has an approved vaccine and several licensed treatments, the Bundibugyo virus has none. Existing Ebola countermeasures were developed and certified for a different species entirely, leaving frontline responders with far fewer tools than they’d normally have at this stage of an outbreak.

The Toll on Health Workers

The WHO Ebola response has repeatedly flagged the disproportionate burden falling on medical staff. More than 100 healthcare workers have been infected since the outbreak began, and around 35 have died — a toll made worse by chronic shortages of protective equipment and, in some communities, outright hostility toward medical teams. In Ituri, some health workers have gone on strike over unpaid wages and unsafe working conditions, further straining a response that was already stretched thin. Facilities have also come under direct attack: a hospital and treatment centre in the Nyakunde health zone were targeted in mid-July, forcing international partners to temporarily relocate and disrupting contact tracing and supply chains at a critical moment.

Community mistrust has compounded the problem. In several areas, residents have questioned whether the disease is even real, and there have been reports of patients fleeing treatment centres and of attacks on burial teams. All of this makes an already difficult epidemiological picture harder to manage, since roughly two-thirds of deaths are occurring among people who never made it to a health facility at all — a pattern that raises the risk of continued community transmission.

Treatment and Vaccine Trials Moving at Record Speed

Despite the grim numbers, the WHO says the scientific response has moved unusually quickly. Vasee Moorthy, acting head of the WHO’s R&D Blueprint programme, told reporters in Geneva that research protocols drafted before this outbreak even began have allowed trials to start far sooner than in past epidemics.

A prophylaxis study led by the DRC’s National Institute for Biomedical Research, working with international partners, has enrolled more than 25 high-risk contacts in Ituri to test whether a 10-day course of the oral antiviral Obeldesivir can prevent disease after exposure. Four testing sites have now opened across the province to support this and other trials, with patients able to enrol and be monitored under safe conditions.

On the vaccine front, two Bundibugyo-specific candidates have entered clinical trials for the first time ever. One, developed jointly by the University of Oxford and the Serum Institute of India, began a phase 1 trial in Britain on July 24. A second candidate from Moderna is expected to start its own phase 1 trial in Canada around the same period. Neither vaccine is yet approved or proven effective, but their arrival at the clinical trial stage marks real progress against a strain that has never before had a dedicated vaccine candidate this far along.

What Comes Next

WHO Director-General Dr. Tedros Adhanom Ghebreyesus has acknowledged that, despite this progress, the outbreak in the DRC continues to outpace the response, with intense transmission in Ituri remaining the organization’s biggest concern. Neighbouring Uganda, which recorded 20 cases linked to cross-border spread, managed to declare its own outbreak over in late July after going 12 days without a new case — a result officials credited to being able to trace every case back to a documented point of entry.

For the DRC itself, the picture remains far more difficult. Conflict in the region continues to hamper access to affected communities, funding shortfalls have added pressure to an already overstretched health system, and the sheer scale of this Africa disease outbreak means the coming weeks will be pivotal both for containing the virus on the ground and for determining whether the treatments and vaccines now in trial can be fielded in time to make a real difference.

The post DRC’s Ebola Outbreak Advances Treatment and Vaccine Trials as WHO Tracks Spread. appeared first on POLYTIKAL.

Walk down any supermarket aisle in India and you’ll spot it everywhere — bottles and packets proudly stamped with “100% Natural,” “100% Pure,” or “100% Organic.” It’s a phrase brands love because it sounds reassuring. But India’s food regulator has just told one of the country’s biggest FMCG names that this kind of labelling has to stop, at least in the form it’s been used.

What the Order Actually Says

The Food Safety and Standards Authority of India, better known as FSSAI, has directed Dabur India to immediately halt the sale of several products carrying “100%” claims on their packaging and website. According to the regulator, these claims — things like “100% Pure,” “100% Purity Guaranteed,” and “100% Tender Coconut Water” — violate the Food Safety and Standards (Advertising & Claims) Regulations, 2018. The core issue, as FSSAI put it, is that such claims are vague, impossible to independently verify, and carry real potential to mislead the average shopper.

The products flagged in this FSSAI Dabur India order span a fairly wide range: honey, apple cider vinegar, virgin coconut oil, sesame oil, cow ghee, coconut water, and coconut milk. In one specific case, the regulator pointed out that Dabur’s Hommade Coconut Milk carried a “100% Purity” claim, which isn’t something that’s even allowed for compound foods — products made by blending multiple ingredients together, where absolute purity as a concept doesn’t really apply.

There’s also an organic-labelling angle to this. FSSAI alleged that two of Dabur’s products, an apple cider vinegar and an organic honey, were displaying the Jaivik Bharat logo — India’s official organic certification mark — without having a valid FSSAI organic endorsement to back it up. That’s a separate but related compliance issue, since using a certification symbol without proper backing can be just as misleading as an unverifiable claim.

This Isn’t the First Warning

What makes this development notable is that it isn’t coming out of nowhere. FSSAI says it had already asked Dabur once before to drop these claims, but the company reportedly hadn’t taken satisfactory corrective action. This time, the regulator isn’t just issuing an advisory — it’s a formal prohibition order, directing Dabur to immediately stop selling the named products, along with any other items in its lineup carrying similar 100% claims. The company has also been asked to submit an action-taken report within 15 days, spelling out exactly how it plans to comply.

Dabur has not yet issued a detailed public response to the order, though given the scale of the products involved, some kind of statement or corrective packaging update seems likely in the days ahead.

Part of a Bigger Pattern

This isn’t really an isolated case of Dabur being singled out — it fits into a much broader push by FSSAI against absolute, unverifiable claims across the packaged food industry. The regulator has taken similar action before. Reconstituted fruit juices, for instance, were previously barred from carrying “100%” labelling because the process of reconstitution — turning concentrate back into juice — makes an absolute purity claim technically inaccurate. More recently, FSSAI also cracked down on drinks marketed using the term “ORS,” after health experts flagged that many sugary beverages were being deceptively branded as oral rehydration solutions, potentially putting children’s health at risk.

Taken together, these moves point to a regulator that’s becoming noticeably more assertive about food safety regulation in India, especially when it comes to how products are marketed rather than just what’s inside them. For a term as broad and appealing as “100 per cent,” this kind of scrutiny was arguably overdue — precision in labelling matters a lot when millions of households are making daily purchasing decisions based on what’s printed on the front of a package.

Why This Matters to Consumers

Consumer rights advocates have largely welcomed this Dabur 100 percent claim ban, and it’s easy to see why. As more Indian households shift toward packaged and processed foods for convenience, the gap between what a label promises and what a product actually delivers becomes a bigger deal, not a smaller one. A claim like “100% Pure” sounds simple, but it’s also nearly impossible for an average buyer to verify on their own — which is exactly the kind of asymmetry that regulation is meant to correct.

This latest FSSAI enforcement 2026 action also sends a signal to the wider FMCG sector: an earlier warning that goes unaddressed can escalate into a formal, public prohibition order. For a company as large and well-established as Dabur, that’s not just a compliance headache — it’s a reputational one too. Whether other major food brands take this as a cue to review their own labelling practices before facing similar action remains to be seen, but the message from the regulator seems pretty clear: vague, unverifiable perfection claims are no longer going to fly quietly under the radar.

The post FSSAI Bars Dabur India From Misleading “100 Per Cent” Product Claims. appeared first on POLYTIKAL.